3,5-diisopropylsalicylic acid and Hypertension, Portal

3,5-diisopropylsalicylic acid has been researched along with Hypertension, Portal in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Artru, F; Denys, A; Moschouri, E	1

Reviews

1 review(s) available for 3,5-diisopropylsalicylic acid and Hypertension, Portal

Article	Year
Direct intrahepatic portocaval shunt (DIPS) or transjugular transcaval intrahepatic portosystemic shunt (TTIPS) to treat complications of portal hypertension: Indications, technique, and outcomes beyond Budd-Chiari syndrome. Clinics and research in hepatology and gastroenterology, 2022, Volume: 46, Issue:4 Topics: Budd-Chiari Syndrome; Humans; Hypertension, Portal; Liver Cirrhosis; Portasystemic Shunt, Transjugular Intrahepatic; Salicylates; Treatment Outcome	2022

Article

Year

Direct intrahepatic portocaval shunt (DIPS) or transjugular transcaval intrahepatic portosystemic shunt (TTIPS) to treat complications of portal hypertension: Indications, technique, and outcomes beyond Budd-Chiari syndrome.

Clinics and research in hepatology and gastroenterology, 2022, Volume: 46, Issue:4

Topics: Budd-Chiari Syndrome; Humans; Hypertension, Portal; Liver Cirrhosis; Portasystemic Shunt, Transjugular Intrahepatic; Salicylates; Treatment Outcome

2022